Literature DB >> 23745812

MicroRNAs in cardiovascular therapeutics.

Gerasimos Siasos1, Dimitris Tousoulis, Panagiotis Tourikis, Savas Mazaris, Giorgos Zakynthinos, Evangelos Oikonomou, Eleni Kokkou, Christina Kollia, Christodoulos Stefanadis.   

Abstract

Recent research reveals the crucial role microRNAs (miRNAs) in the pathogenesis and progression of many pathological conditions, including cardiovascular diseases. It is widely documented that miRNAs represent critical regulators of cardiovascular function and participate in almost all aspects of cardiovascular biology. In particular, they are involved in several pathophysiological pathways of various manifestations of cardiovascular disease, such as coronary artery disease, heart failure, stroke, diabetes mellitus, arterial hypertension and cardiac arrhythmias. In the present article we review the available literature regarding to the role of miRNAs in certain cardiovascular conditions. Moreover, we discuss the therapeutic potential of miRNAs for treating cardiovascular diseases and we attempt to highlight future directions.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23745812     DOI： 10.2174/15680266113139990109

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  8 in total

Review 1.  RNA viruses and microRNAs: challenging discoveries for the 21st century.

Authors:  Gokul Swaminathan; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

2.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

Review 3.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.

Authors:  Evangelos Oikonomou; Konstantinos Mourouzis; Petros Fountoulakis; Georgios Angelos Papamikroulis; Gerasimos Siasos; Alexis Antonopoulos; Georgia Vogiatzi; Sotiris Tsalamadris; Manolis Vavuranakis; Dimitris Tousoulis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

5.  miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease.

Authors:  Jianqing Zhou; Guofeng Shao; Xiaoliang Chen; Xi Yang; Xiaoyan Huang; Ping Peng; Yanna Ba; Lin Zhang; Tashina Jehangir; Shizhong Bu; Ningsheng Liu; Jiangfang Lian
Journal:  Biosci Rep       Date:  2015-12-18       Impact factor: 3.840

Review 6.  Non-coding RNAs and hypertension-unveiling unexpected mechanisms of hypertension by the dark matter of the genome.

Authors:  Kazuo Murakami
Journal:  Curr Hypertens Rev       Date:  2015

Review 7.  Editorial focus: entering into the non-coding RNA era.

Authors:  Rafal Bartoszewski; Aleksander F Sikorski
Journal:  Cell Mol Biol Lett       Date:  2018-09-18       Impact factor: 5.787

Review 8.  Editorial focus: understanding off-target effects as the key to successful RNAi therapy.

Authors:  Rafal Bartoszewski; Aleksander F Sikorski
Journal:  Cell Mol Biol Lett       Date:  2019-12-09       Impact factor: 5.787
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.